Posted: Tuesday, September 13, 2022
According to Gwenaëlle Gravis Mescam, MD, of Institut Paoli Calmettes, Marseille, France, and colleagues, the 8-month prostate-specific antigen (PSA) value strongly predicts both radiologic progression-free and overall survival in patients with metastatic castration-sensitive prostate cancer who were treated with androgen-deprivation therapy (ADT) with or without docetaxel and abiraterone acetate plus prednisone. The results of this preplanned analysis of the phase III PEACE-1 trial, which were presented during the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract 1361MO), support further investigation of early therapeutic intervention in those with unfavorable 8-month PSA values.
Using 8-month PSA cutoff values of 0.2 and 4.0 ng/mL, the investigators analyzed data from 931 patients. The standard of care was ADT plus docetaxel in 62% of this population. A total of 56% of patients had “high-volume” disease. Follow-up data were provided for a median of 4.4 years.
At PSA values of less than 0.2, greater than 0.2, less than 4.0, and greater than 4.0 ng/mL, the median durations of radiologic progression-free survival were 4.0, 1.4, 2.5, and 0.7 years with ADT with or without docetaxel; 3.7, 1.3, 2.1, and 0.5 years with ADT plus docetaxel; not reached, 2.2, 5.4, and 0.7 years with ADT plus abiraterone acetate plus prednisone with or without docetaxel; and 4.7, 2.5, 4.5, and 0.7 years with ADT plus abiraterone acetate plus prednisone and docetaxel, respectively. The median durations of overall survival were not reached, 3.5, 5.9, and 2.1 years with ADT with or without docetaxel; not reached, 3.5, 4.5, and 2.1 years with ADT plus docetaxel; not reached, 3.4, 6.1, and 1.5 years with ADT plus abiraterone acetate plus prednisone with or without docetaxel; and not reached, 3.6, not reached, and 1.6 years with ADT plus abiraterone acetate plus prednisone and docetaxel, respectively.
Disclosure: For full disclosures of the study authors, visit cslide.ctimeetingtech.com.